NovaBay Pharmaceuticals (NBY) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 07, 2023
Document Information [Line Items]
Entity Central Index Key	0001389545
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-33678
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0454536
Entity Address, Address Line One	2000 Powell Street, Suite 1150
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	899-8800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	NBY
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,728,824

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 3,746	$ 5,362
Accounts receivable, net of allowance for credit losses ($3 and $19 at March 31, 2023 and December 31, 2022, respectively)	1,835	1,973
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($488 and $499 at March 31, 2023 and December 31, 2022, respectively)	3,797	3,437
Prepaid expenses and other current assets	516	560
Total current assets	9,894	11,332
Operating lease right-of-use assets	1,744	1,831
Property and equipment, net	119	119
Goodwill	348	348
Other intangible assets, net	2,242	2,280
Other assets	478	489
TOTAL ASSETS	14,825	16,399
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	1,148	1,080
Accrued liabilities	2,809	2,724
Operating lease liabilities	466	453
Total current liabilities	4,423	4,257
Operating lease liabilities-non-current	1,512	1,588
Total liabilities	5,935	5,845
Commitments & contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.01 par value; 150,000 shares authorized, 2,035 shares issued and outstanding at March 31, 2023 and December 31, 2022	652	652
Additional paid-in capital	165,156	165,081
Accumulated deficit	(159,891)	(158,152)
Total stockholders’ equity	8,890	10,554
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	14,825	16,399
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	570	570
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	$ 2,403	$ 2,403

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable, allowance for doubtful accounts	$ 3	$ 19
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 488	$ 499
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	2,035,000	2,035,000
Common stock, shares outstanding (in shares)	2,035,000	2,035,000
Series B Preferred Stock [Member]
Preferred stock, shares issued (in shares)	12,000	12,000
Preferred stock, shares outstanding (in shares)	12,000	12,000
Series C Preferred Stock [Member]
Preferred stock, shares issued (in shares)	2,000	2,000
Preferred stock, shares outstanding (in shares)	2,000	2,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Sales:
Total sales, net	$ 3,124	$ 3,273
Product cost of goods sold	1,188	1,459
Gross profit	1,936	1,814
Operating expenses:
Research and development	26	28
Sales and marketing	1,653	1,985
General and administrative	1,991	2,183
Total operating expenses	3,670	4,196
Operating loss	(1,734)	(2,382)
Non-cash gain on changes in fair value of warrant liability	0	2,056
Non-cash gain on changes in fair value of contingent liability	0	219
Other expense, net	(5)	(4)
Net loss	$ (1,739)	$ (111)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.85)	$ (0.08)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares)	2,035	1,431
Product [Member]
Sales:
Total sales, net	$ 3,117	$ 3,267
Product and Service, Other [Member]
Sales:
Total sales, net	$ 7	$ 6

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	14	1,365
Balance at Dec. 31, 2021	$ 680	$ 478	$ 150,900	$ (141,887)	$ 10,171
Net Loss				(111)	(111)
Stock-based compensation expense related to employee and director stock awards	$ 0	$ 0	184	0	184
Balance (in shares) at Dec. 31, 2022	14	2,035
Balance at Dec. 31, 2022	$ 2,973	$ 652	165,081	(158,152)	10,554
Net Loss	0	0	0	(1,739)	(1,739)
Stock-based compensation expense related to employee and director stock awards	$ 0	$ 0	$ 75	$ 0	$ 75

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Series B Private Placement Warrants [Member] Preferred Stock [Member]	Series B Private Placement Warrants [Member] Common Stock [Member]	Series B Private Placement Warrants [Member] Additional Paid-in Capital [Member]	Series B Private Placement Warrants [Member] Retained Earnings [Member]	Series B Private Placement Warrants [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021						14	1,365
Balance at Dec. 31, 2021						$ 680	$ 478	$ 150,900	$ (141,887)	$ 10,171
Net Loss									(111)	(111)
Reclassification of Private Placement Warrants	$ 0	$ 0	$ 7,502	$ 0	$ 7,502
Conversion of preferred stock to common stock (in shares)						(1)	104
Conversion of Series B Preferred Stock						$ (71)	$ (36)	(35)	0	0
Conversion of Series B Preferred Stock						71	36	35	0	0
Stock-based compensation expense related to employee and director stock awards						$ 0	$ 0	184	0	184
Balance (in shares) at Mar. 31, 2022						13	1,469
Balance at Mar. 31, 2022						$ 609	$ 514	158,621	(141,998)	17,746
Balance (in shares) at Dec. 31, 2022						14	2,035
Balance at Dec. 31, 2022						$ 2,973	$ 652	165,081	(158,152)	10,554
Net Loss						0	0	0	(1,739)	(1,739)
Stock-based compensation expense related to employee and director stock awards						$ 0	$ 0	75	0	75
Balance (in shares) at Mar. 31, 2023						14	2,035
Balance at Mar. 31, 2023						$ 2,973	$ 652	$ 165,156	$ (159,891)	$ 8,890

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (1,739)	$ (111)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	13	30
Amortization of intangible assets	38	91
Non-cash gain on changes in fair value of warrant liability	0	(2,056)
Non-cash gain on changes in fair value of contingent liability	0	(219)
Changes in operating assets and liabilities:
Accounts receivable	138	(632)
Inventory	(360)	(565)
Prepaid expenses and other current assets	44	26
Operating lease right-of-use assets	87	(1,920)
Other assets	3	(8)
Accounts payable and accrued liabilities	153	1,182
Operating lease liabilities	(63)	1,941
Net cash used in operating activities	(1,611)	(2,057)
Investing activities:
Purchases of property and equipment	(13)	(24)
Net cash used in investing activities	(13)	(24)
Financing activities:
Payment on the line of credit	0	(105)
Net cash used in financing activities	0	(105)
Net change in cash, cash equivalents, and restricted cash	(1,624)	(2,186)
Cash, cash equivalents and restricted cash, beginning of year	5,846	7,979
Cash, cash equivalents and restricted cash, end of period	4,222	5,793
Supplemental disclosure of cash flow information:
Interest paid	5	4
Warrant liability transferred to equity	0	7,502
Addition of operating lease, right-of-use asset	0	2,039
Conversion of Series B Preferred Stock		0
Employees and Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense related to employee and director stock awards	75	184
Conversion of Series B Preferred Stock to Common Stock [Member]
Supplemental disclosure of cash flow information:
Conversion of Series B Preferred Stock	$ 0	$ 71

Note 1 - Organization

Note 1 - Organization	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION NovaBay Pharmaceuticals, Inc. (the “Company”) develops and sells scientifically-created and clinically-proven eyecare, skincare and wound care products. Our leading product, Avenova® Antimicrobial Lid and Lash Solution, or Avenova Spray, is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the FDA for sale in the United States. Avenova Spray is available direct to consumers primarily through online distribution channels and is also available by prescription and dispensed by eyecare professionals for blepharitis and dry-eye disease. Other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress, and the i-Chek eyelid and eyelash mirror by Avenova. Through our subsidiary DERMAdoctor, LLC (“DERMAdoctor”), the Company offers over 30 November 2021 ( The Company also manufactures and sells its proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for the cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors. The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, 1 2 Effective November 15, 2022, 1 12, 1 35 Liquidity and Going Concern Based primarily on the funds available on March 31, 2023 2023 March 31, 2023 18, second 2024. 2023 2023 may may 19 The Company’s long-term liquidity needs will be largely determined by the success of commercialization efforts. To address the Company’s current liquidity and capital needs, the Company has and continues to evaluate different plans and strategic transactions to fund operations, including: ( 1 2 one 3 4 may may 1 3 not may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. These estimates include contract liabilities related to product sales such as product returns, assumptions for valuing warrants, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies. These estimates are based on management’s best estimates and judgment. Actual results may Unaudited Condensed Consolidated Interim Financial Information The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not not The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2022, 10 December 31, 2022, March 31, 2023. Change in Accounting and Revision of Prior Period Financial Statements During the third 2022, third no not While reviewing its accounting policy for fulfillment fees during the third 2022, third third 2022, 2022 first second 2021 no not Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2023 December 31, 2022, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): March 31, December 31, 2023 2022 Cash and cash equivalents $ 3,746 $ 5,362 Restricted cash included in other assets 476 484 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 4,222 $ 5,846 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. During the three March 31, 2023 2022, During the three March 31, 2023 2022, For the three Months Ended March 31, 2023 2022 Avenova Spray $ 1,937 $ 1,839 DERMAdoctor 785 1,043 NeutroPhase — 148 Other products 395 237 Total product revenue, net 3,117 3,267 Other revenue, net 7 6 Total sales, net $ 3,124 $ 3,273 During the three March 31, 2023 2022, No 10% three March 31, 2023 2022. As of March 31, 2023 December 31, 2022, 10% March 31, December 31, Major distribution partner 2023 2022 Avenova Spray Pharmacy Distributor A 35 % 30 % Major U.S. Retailer A 15 % * % Major U.S. Retailer B 12 % * % Major U.S. Retailer C * % 15 % Avenova Spray Pharmacy Distributor B * % 11 % * Less than 10% The Company relies on seven not third may may not may Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows ASC 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. Management recorded a reserve for allowance for credit losses of $3 thousand and $19 thousand as of March 31, 2023 December 31, 2022, Inventory Inventory is comprised of ( 1 2 3 first first March 31, 2023 December 31, 2022, Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may may one not The Company did not three March 31, 2023 2022. Valuation of Contingent Consideration Resulting from a Business Combination In connection with certain acquisitions, including the DERMAdoctor Acquisition, the Company may Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period. Actual results may DERMAdoctor Acquisition milestone events consist of financial targets for calendar years 2022 2023. not 2022. not 2023. zero March 31, 2023 December 31, 2022. Long-Lived Assets The Company’s intangible assets that do not 360, Property, Plant and Equipment may may not no not The Company did not three March 31, 2023 2022. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Revenue Recognition Revenue is recognized from the sale of goods in accordance with ASC 606, Revenue from Contracts with Customers 606, 606, five 606: i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is generated through the Company’s webstores, Avenova.com and DERMAdoctor.com, for Avenova and DERMAdoctor products. Such direct to consumer sales are recognized upon fulfillment, which generally occurs upon delivery of the related products to a third Revenue generated through third third The Company pays third third 2022, third 2022, Prior to the third 2022, third not third 2022, third 2022, not not Prior to the third 2022, third 2022, third 2022 2022 2021 2021 2020 no not Financial statement line items included in the condensed consolidated statements of operations for the three March 31, 2022 For the Three Months Ended March 31, 2022 As Previously Reported Selling Commissions Fulfillment Fees As Revised Sales Product revenue, net $ 2,623 $ 298 $ 346 $ 3,267 Product cost of goods sold Product cost of goods sold 1,113 - 346 1,459 Operating expenses Sales and marketing 1,687 298 - 1,985 Net loss (111 ) - - (111 ) Net loss per share attributable to common stockholders (basic and diluted) (0.08 ) - - (0.08 ) The Company also generates Avenova Spray revenue through major pharmacy distribution partners. Product supply of Avenova Spray is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon delivery to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return and other contract liabilities from historical data and updates its assumptions quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor. Revenue for products sales to Costco is recognized upon transfer of control at the amount of consideration that the Company expects to be entitled to, generally upon delivery to Costco. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to reversal, including discounts and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to Costco. Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to other retailers, such as CVS, is generally recognized upon transfer of control to the retailer, which generally occurs upon delivery of the products to a third The Company may March 31, 2023 December 31, 2022, Cost of Goods Sold Cost of goods sold includes third third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (the “FDA”). Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations. Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $326 thousand and $617 thousand for the three March 31, 2023 2022, Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and RSUs to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s unaudited condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrants The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) do not For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment. Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. The following table sets forth the calculation of basic EPS and diluted EPS (in thousands, except per share amounts): Three Months Ended March 31, Numerator 2023 2022 Net loss $ (1,739 ) $ (111 ) Denominator Weighted average shares of common stock outstanding (basic and diluted) 2,035 1,431 Net loss per share attributable to common stockholders (basic and diluted) $ (0.85 ) $ (0.08 ) For the three March 31, 2023 2022, not The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands): Three Months Ended March 31, 2023 2022 Stock options 121 126 Stock warrants 2,306 1,274 2,427 1,400 Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, 10 December 31, 2022, March 31, 2023. In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 2016 13 January 1, 2023. January 1, 2023, not

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The Company’s cash equivalents are classified within Level 1 1 The following table presents the Company’s cash equivalent assets measured at fair value on a recurring basis as of March 31, 2023 ( Fair Value Measurements Using Quoted Prices in Active Significant Markets Other Significant Balance at for Identical Observable Unobservable March 31, Items Inputs Inputs 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 152 152 — — Total assets $ 476 $ 476 $ — $ — The following table presents the Company’s cash equivalent assets measured at fair value on a recurring basis as of December 31, 2022 ( Fair Value Measurements Using Quoted Prices in Active Significant Markets Other Significant Balance at for Identical Observable Unobservable December 31, Items Inputs Inputs 2022 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 332 $ 332 $ — $ — Deposit held as a certificate of deposit 152 152 — — Total assets $ 484 $ 484 $ — $ —

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, 2023 2022 Prepaid inventory $ 122 $ 211 Prepaid insurance 119 146 Prepaid dues and subscriptions 99 43 Prepaid marketing costs 40 24 Prepaid patents 4 12 Tenant allowance — 11 Other 132 113 Total prepaid expenses and other current assets $ 516 $ 560

Note 5 - Inventory

Note 5 - Inventory	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following (in thousands): March 31, December 31, 2023 2022 Raw materials and supplies $ 1,080 $ 1,273 Finished goods 3,205 2,663 Less: Reserve for excess and obsolete inventory (488 ) (499 ) Total inventory, net $ 3,797 $ 3,437

Note 6 - Property and Equipment

Note 6 - Property and Equipment	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following (in thousands): March 31, December 31, 2023 2022 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 425 412 Leasehold improvements 152 152 Total property and equipment, at cost 754 741 Less: accumulated depreciation (635 ) (622 ) Total property and equipment, net $ 119 $ 119 Depreciation expense was $13 thousand and $30 thousand for the three March 31, 2023 2022,

Note 7 - Other Intangible Asset

Note 7 - Other Intangible Assets	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 7. Other intangible assets consist of the following (in thousands): Balance at March 31, 2023 Accumulated Gross Amortization Impairment Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (970 ) $ 1,110 Amortizable intangible assets Customer relationships $ 290 $ (51 ) $ (172 ) $ 67 Trade secrets / product formulations 2,890 (410 ) (1,415 ) 1,065 Total other intangible assets $ 5,260 $ (461 ) $ (2,557 ) $ 2,242 Balance at December 31, 2022 Accumulated Gross Amortization Impairment Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (970 ) $ 1,110 Amortizable intangible assets Customer relationships $ 290 $ (48 ) $ (172 ) $ 70 Trade secrets / product formulations 2,890 (375 ) (1,415 ) 1,100 Total other intangible assets $ 5,260 $ (423 ) $ (2,557 ) $ 2,280 In the fourth 2022, fourth 2022, not three March 31, 2023 2022. Amortization expense was $38 thousand and $91 thousand for the three March 31, 2023 2022, March 31, 2023, 2023 $ 114 2024 153 2025 152 2026 153 Thereafter 560 Total $ 1,132

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 8. Accrued liabilities consisted of the following (in thousands): March 31, December 31, 2023 2022 Contract liabilities (see Note 14) $ 1,864 $ 1,807 Employee payroll and benefits 402 261 Marketing costs 49 104 Inventory purchases 14 101 Other 480 451 Total accrued liabilities $ 2,809 $ 2,724

Note 9 - Line of Credit

Note 9 - Line of Credit	3 Months Ended
	Mar. 31, 2023
Line of Credit [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 9. At the time of the DERMAdoctor Acquisition, DERMAdoctor had a line of credit agreement with Bank Midwest for $500 thousand. As of March 31, 2023 December 31, 2022, March 31, 2022.

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 10. Indemnification Agreements As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not March 31, 2023 December 31, 2022. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not March 31, 2023 December 31, 2022. Legal Matters As of March 31, 2023 December 31, 2022, no Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The initial lease term was scheduled to expire on February 28, 2022, January 19, 2022, July 31, 2027. The Company is also party to a lease for 19,136 square feet of space located in Riverside, Missouri, which it utilizes for light manufacturing, storage, distribution of products and administrative functions. The lease commenced on October 1, 2019 December 31, 2024. In calculating the present value of the minimum lease payments, the Company utilized its incremental borrowing rate. The Company has elected to account for each lease component and its associated non-lease components as a single lease component and has allocated all of the contract consideration across lease components only. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not not The components of lease expense for the three March 31, 2023 2022 Lease Costs Three Months Ended March 31, 2023 2022 Operating lease cost $ 130 $ 134 Net lease cost $ 130 $ 134 Other information Operational cash flow used for operating leases $ 106 $ 111 The Company has measured its operating lease liabilities at its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows: Three Months Ended March 31, 2023 2022 Weighted-average remaining lease term (in years) 4.0 5.0 Weighted-average discount rate 5 % 5 % Future lease payments under non-cancelable leases as of March 31, 2023 2023 $ 437 2024 557 2025 439 2026 444 2027 290 Total future minimum lease payments 2,167 Less imputed interest (189 ) Total $ 1,978 Reported as: Operating lease liabilities $ 466 Operating lease liabilities- non-current 1,512 Total $ 1,978

Note 11 - Warrant Liability

Note 11 - Warrant Liability	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 11. See additional discussion of the terms of the Company’s various warrants and related transactions in Note 12, 12, September 2022 The September 2022 September 9, 2022, 2022 September 2022 not November 10, 2022. 480, Distinguishing Liabilities from Equity September 2022 The fair value of the September 2022 September 9, 2022 Expected price volatility 79.6 % Expected term (in years) 6.0 Risk-free interest rate 3.43 % Dividend yield 0.0 % Weighted-average fair value of warrants $ 4.55 The fair value of the September 2022 November 10, 2022 Expected price volatility 79.5 % Expected term (in years) 5.8 Risk-free interest rate 3.93 % Dividend yield 0.0 % Weighted-average fair value of warrants $ 1.40 November 2021 The November 2021 November 2, 2021, 2021 November 2021 September 2022 2022 The November 2021 not January 31, 2022. 480, Distinguishing Liabilities from Equity November 2021 As of December 31, 2021 November 2021 Expected price volatility 87 % Expected term (in years) 6.0 Risk-free interest rate 1.31 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 8.75 As of January 31, 2022, November 2021 Expected price volatility 91 % Expected term (in years) 6.0 Risk-free interest rate 1.65 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 7.00 Unexercised November 2021 September 9, 2022, 2022 November 2021 no November 10, 2022. 480, Distinguishing Liabilities from Equity November 2021 The fair value of these November 2021 September 9, 2022 Expected price volatility 79.6 % Expected term (in years) 6.0 Risk-free interest rate 3.43 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 4.55 As of November 10, 2022, November 2021 Expected price volatility 79.5 % Expected term (in years) 5.8 Risk-free interest rate 3.93 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.40 Amended July 2020 On September 9, 2022, 2022 July 2020 July 2020 no November 10, 2022. 480, Distinguishing Liabilities from Equity July 2020 The fair value of these Amended July 2020 September 9, 2022 Expected price volatility 79.6 % Expected term (in years) 3.4 Risk-free interest rate 3.58 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 3.50 As of November 10, 2022, July 2020 Expected price volatility 79.5 % Expected term (in years) 3.2 Risk-free interest rate 4.15 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.05

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Equity [Text Block]	NOTE 12. Common Stock and Preferred Stock Under the Company’s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock (with rights and preferences as may Reverse Stock Split Effective November 15, 2022, 1 November 10, 2022. 35 1 not 35 35. 1 2022 November 2021 July 2020 September 2022 On September 9, 2022, 2022 November 2021 July 2020 November 2021 July 2020 not March 9, 2023; November 2021 September 11, 2028 ( November 2021 July 2020 November 2021 September 11, 2028. July 2020 January 22, 2026. As a result of these amendments to the Amended November 2021 July 2020 $1.9 November 2021 July 2020 November 2021 July 2020 November 2021 Warrants July 2020 Warrants Expected price volatility 79.6 % 79.6 % Expected term (in years) 5.4 3.4 Risk-free interest rate 3.43 % 3.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.15 $ 0.70 The fair value of the Amended November 2021 July 2020 November 2021 Warrants July 2020 Warrants Expected price volatility 79.6 % 79.6 % Expected term (in years) 6.0 3.4 Risk-free interest rate 3.43 % 3.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 4.55 $ 3.50 Additionally, in connection with the 2022 2022 November 2021 July 2020 “September 2022 100% November 2021 July 2020 September 2022 September 11, 2028. The 2022 November 2021 July 2020 September 2022 November 2021 July 2020 September 2022 11 , Ladenburg Thalmann & Co. Inc. (“Ladenburg”) served as the Company’s warrant solicitation agent for the 2022 2022 third 2022 . Series C Preferred Stock, Short-Term Warrants and Long-Term Warrants Concurrent with the 2022 September 9, 2022, “2022 1 2 2 May 20, 2024 ( 3 1 November 20, 2028 ( “2022 2022 November 10, 2022), November 18, 2022, 2022 2022 The Series C Preferred Stock does not Series B Preferred Stock and November 2021 On October 29, 2021, 2021 November 2021 2021 November 2, 2021. November 2021 January 31, 2022, six 6 The Series B Preferred Stock does not Each share of the Series B Preferred Stock that the Company issued in the 2021 37,500,000 not September 9, 2022, 2022 September 2022 not not third 2022. 820, 1 2 Expected price volatility 79.6 % Expected term (in years) 1.3 Risk-free interest rate 3.64 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 8.05 The fair value of the Series B Preferred Stock was determined to be $12.5 Expected price volatility 79.6 % Expected term (in years) 1.3 Risk-free interest rate 3.64 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.10 Thereafter, the Company effected the Reverse Stock Split, which resulted in an automatic adjustment to the conversion price for each outstanding share of the Series B Preferred Stock to $6.30, 159 As of March 31, 2023, March 31, 2023, 18. On September 9, 2022, 2022 November 2021 September 11, 2028. 2022 November 2021 March 31, 2023, November 2021 Common Stock Common Stock Warrants In addition to the Amended July 2020 November 2021 September 2022 2022 2019 In 2019, “2019 2019 August 8, 2024. July 2020 In 2020, “July 2020 July 2020 March 31, 2023, July 2020 not July 2020 January 22, 2026. TLF Bio Innovation 2021 In 2021, January 15, 2026. Summary of Warrants Outstanding The details of all outstanding warrants as of March 31, 2023 December 31, 2022 Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2022 2,306 $ 7.70 Warrants granted — $ — Warrants expired — $ — Outstanding at March 31, 2023 2,306 $ 7.70

Note 13 - Equity-based Compensa

Note 13 - Equity-based Compensation	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 13. Equity Compensation Plans In October 2007, 2007 “2007 2007 March 15, 2017. 2007 2007 no ten 2007 December 31, 2020. In March 2017, 2017 “2017 June 2, 2017, 2017 not 2007 2017 first January 1, 2018 January 1, 2027 4 2017 March 31, 2023, 2017 March 31, 2023, 2017 Under the terms of the 2017 may not not not ten not five 10% four 2007 2017 Summary of Outstanding Equity Awards The following table summarizes information about the Company’s equity awards outstanding at March 31, 2023 March 31, 2023: (in thousands, except years and per share data) Awards Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2022 132 $ 37.99 7.5 $ 69 Options granted 4 $ 1.80 Options forfeited/cancelled (5 ) $ 59.45 Restricted stock units cancelled (7 ) — Outstanding at March 31, 2023 124 $ 38.34 7.3 $ 48 Vested and expected to vest at March 31, 2023 95 $ 49.23 6.9 $ 9 Vested at March 31, 2023 66 $ 65.02 6.1 $ — Exercisable at March 31, 2023 66 $ 65.02 6.1 $ — The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of March 31, 2023 three March 31, 2023 2022. no three March 31, 2023 2022. As of March 31, 2023, Equity Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the three March 31, 2023 2022, The weighted-average assumptions used in determining the value of options are as follows: Three Months Ended March 31, Assumption 2023 2022 Expected price volatility 154.49 % 160.47 % Expected term (in years) 6.66 6.45 Risk-free interest rate 3.41 % 1.63 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.37 $ 10.21 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. During the three March 31, 2023 2022, not For the three March 31, 2023 2022, Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands): Three Months Ended March 31, 2023 2022 Research and development $ 6 $ 4 Sales and marketing 15 12 General and administrative 54 168 Total stock-based compensation expense $ 75 $ 184

Note 14 - Distribution Agreemen

Note 14 - Distribution Agreements	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
License, Collaboration, and Distribution Agreements [Text Block]	NOTE 14. Transactions under the Company’s major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. Product Sales Discounts and Allowances The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration for the three March 31, 2023 ( Product Returns, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2022 $ 1,673 $ 53 $ 81 $ 1,807 Provision related to sales made in current period 254 21 401 676 Payments and customer credits issued (188 ) (8 ) (423 ) (619 ) Balance at March 31, 2023 $ 1,739 $ 66 $ 59 $ 1,864 Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three March 31, 2023, three March 31, 2022 Under these product distribution arrangements, the Company had a contract liability balance of $1.5 million as of March 31, 2023 December 31, 2022. March 31, 2023, December 31, 2022, 4, Over-the-Counter Sales of Avenova Spray Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com), Walmart.com, select CVS stores and online on CVS.com. During the three March 31, 2023 2022, DERMAdoctor Products Distribution Agreements DERMAdoctor products are sold through distribution arrangements with third three March 31, 2023 2022, Under these distribution arrangements, the Company had a contract liability balance of $0.3 million as of March 31, 2023, December 31, 2022.

Note 15 - Employee Benefit Plan

Note 15 - Employee Benefit Plan	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 15. The Company has a 401 first three March 31, 2023 2022,

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 16. Related Party Revenue The following table summarizes information about the Company’s related party revenue and cost of goods sold (in thousands): Three Months Ended March 31, 2023 2022 Related party revenue: NeutroPhase $ — $ 148 Total related party revenue $ — $ 148 Cost of goods sold: NeutroPhase $ — $ (134 ) Total related party expenses $ — $ (134 ) Related party accounts receivable was zero and $0.2 million as of March 31, 2023 December 31, 2022,

Note 17 - Segment Reporting

Note 17 - Segment Reporting	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 17. The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. Prior to the DERMAdoctor Acquisition in November 2021, 1 2 Select financial information for each segment is as follows: Three Months Three Months Ended Percentage Ended Percentage March 31, of Total Sales, March 31, of Total Sales, 2023 Net 2022 Net Eyecare & Wound Care $ 2,339 75 % $ 2,230 68 % Skincare 785 25 % 1,043 32 % Total sales, net $ 3,124 100 % $ 3,273 100 % Three Months Three Months Ended Percentage Ended Percentage March 31, of Total March 31, of Total 2023 Operating Loss 2022 Operating Loss Eyecare & Wound Care $ (1,335 ) 77 % $ (2,039 ) 86 % Skincare (399 ) 23 % (343 ) 14 % Total operating loss $ (1,734 ) 100 % $ (2,382 ) 100 %

Note 18 - Subsequent Events

Note 18 - Subsequent Events	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 18. The Company has evaluated all subsequent events through the filing date of this Form 10 March 31, 2023 , not no 2023 On April 27, 2023, “2023 November 1, 2024 ( may 1 five 2 two “2023 2023 May 1, 2023 ( 2023 Due to the number of shares of common stock that may 2023 713 713 sixty 60 2023 2023 not At any time after issuance, the Debentures are convertible by the holder, in whole or in part, into shares of common stock at a conversion price equal to $1.30 per share (“Conversion Price”), subject to limitations upon conversion including the Issuable Maximum. Under the terms of the Debentures, the Company is required to make a monthly redemption of the Debentures (“Monthly Redemption”) beginning on June 1, 2023 1/18th If any event of default occurs, the outstanding principal amount of the Debentures, plus accrued but unpaid interest, liquidated damages and other amounts owing in respect thereof through the date of acceleration, shall become, at the holder’s election, immediately due and payable in cash. Commencing five April 27, 2023 ( Warrant Amendments In connection with the closing of the 2023 Anti-Dilution Adjustment to Series B Preferred Stock and the Series C Preferred Stock The Certificate of Designation of Preferences, Rights and Limitations for the Company’s outstanding Series B Preferred Stock (the “Series B Certificate of Designation”) and the Certificate of Designation of Preferences, Rights and Limitations for the Company’s outstanding Series C Preferred Stock (the “Series C Certificate of Designation”) provides for anti-dilution protections in the event that the Company grants any right to reprice any Company security or issue a new Company security that would entitle the holder to acquire Common Stock at an effective price per share that is lower than the conversion price of the Series B Preferred Stock and the Series C Preferred Stock, which is referred to as “full-ratchet” anti-dilution protection. As a result of the consummation of the 2023 2023

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. These estimates include contract liabilities related to product sales such as product returns, assumptions for valuing warrants, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies. These estimates are based on management’s best estimates and judgment. Actual results may
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Information The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not not The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2022, 10 December 31, 2022, March 31, 2023.
Reclassification, Comparability Adjustment [Policy Text Block]	Change in Accounting and Revision of Prior Period Financial Statements During the third 2022, third no not While reviewing its accounting policy for fulfillment fees during the third 2022, third third 2022, 2022 first second 2021 no not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2023 December 31, 2022, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): March 31, December 31, 2023 2022 Cash and cash equivalents $ 3,746 $ 5,362 Restricted cash included in other assets 476 484 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 4,222 $ 5,846 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. During the three March 31, 2023 2022, During the three March 31, 2023 2022, For the three Months Ended March 31, 2023 2022 Avenova Spray $ 1,937 $ 1,839 DERMAdoctor 785 1,043 NeutroPhase — 148 Other products 395 237 Total product revenue, net 3,117 3,267 Other revenue, net 7 6 Total sales, net $ 3,124 $ 3,273 During the three March 31, 2023 2022, No 10% three March 31, 2023 2022. As of March 31, 2023 December 31, 2022, 10% March 31, December 31, Major distribution partner 2023 2022 Avenova Spray Pharmacy Distributor A 35 % 30 % Major U.S. Retailer A 15 % * % Major U.S. Retailer B 12 % * % Major U.S. Retailer C * % 15 % Avenova Spray Pharmacy Distributor B * % 11 % * Less than 10% The Company relies on seven not third may may not may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows ASC 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. Management recorded a reserve for allowance for credit losses of $3 thousand and $19 thousand as of March 31, 2023 December 31, 2022,
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 first first March 31, 2023 December 31, 2022,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may may one not The Company did not three March 31, 2023 2022.
Valuation of Contingent Consideration from Business Combination Policy [Policy Text Block]	Valuation of Contingent Consideration Resulting from a Business Combination In connection with certain acquisitions, including the DERMAdoctor Acquisition, the Company may Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period. Actual results may DERMAdoctor Acquisition milestone events consist of financial targets for calendar years 2022 2023. not 2022. not 2023. zero March 31, 2023 December 31, 2022.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long-Lived Assets The Company’s intangible assets that do not 360, Property, Plant and Equipment may may not no not The Company did not three March 31, 2023 2022.
Lessee, Leases [Policy Text Block]	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized from the sale of goods in accordance with ASC 606, Revenue from Contracts with Customers 606, 606, five 606: i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is generated through the Company’s webstores, Avenova.com and DERMAdoctor.com, for Avenova and DERMAdoctor products. Such direct to consumer sales are recognized upon fulfillment, which generally occurs upon delivery of the related products to a third Revenue generated through third third The Company pays third third 2022, third 2022, Prior to the third 2022, third not third 2022, third 2022, not not Prior to the third 2022, third 2022, third 2022 2022 2021 2021 2020 no not Financial statement line items included in the condensed consolidated statements of operations for the three March 31, 2022 For the Three Months Ended March 31, 2022 As Previously Reported Selling Commissions Fulfillment Fees As Revised Sales Product revenue, net $ 2,623 $ 298 $ 346 $ 3,267 Product cost of goods sold Product cost of goods sold 1,113 - 346 1,459 Operating expenses Sales and marketing 1,687 298 - 1,985 Net loss (111 ) - - (111 ) Net loss per share attributable to common stockholders (basic and diluted) (0.08 ) - - (0.08 ) The Company also generates Avenova Spray revenue through major pharmacy distribution partners. Product supply of Avenova Spray is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon delivery to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return and other contract liabilities from historical data and updates its assumptions quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor. Revenue for products sales to Costco is recognized upon transfer of control at the amount of consideration that the Company expects to be entitled to, generally upon delivery to Costco. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to reversal, including discounts and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to Costco. Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to other retailers, such as CVS, is generally recognized upon transfer of control to the retailer, which generally occurs upon delivery of the products to a third The Company may March 31, 2023 December 31, 2022,
Cost of Goods Sold [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (the “FDA”).
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations.
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $326 thousand and $617 thousand for the three March 31, 2023 2022,
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and RSUs to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s unaudited condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Warrant Liabilities [Policy Text Block]	Common Stock Warrants The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) do not For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. The following table sets forth the calculation of basic EPS and diluted EPS (in thousands, except per share amounts): Three Months Ended March 31, Numerator 2023 2022 Net loss $ (1,739 ) $ (111 ) Denominator Weighted average shares of common stock outstanding (basic and diluted) 2,035 1,431 Net loss per share attributable to common stockholders (basic and diluted) $ (0.85 ) $ (0.08 ) For the three March 31, 2023 2022, not The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands): Three Months Ended March 31, 2023 2022 Stock options 121 126 Stock warrants 2,306 1,274 2,427 1,400
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, 10 December 31, 2022, March 31, 2023. In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 2016 13 January 1, 2023. January 1, 2023, not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	March 31, December 31, 2023 2022 Cash and cash equivalents $ 3,746 $ 5,362 Restricted cash included in other assets 476 484 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 4,222 $ 5,846
Schedules of Concentration of Risk, by Product [Table Text Block]	For the three Months Ended March 31, 2023 2022 Avenova Spray $ 1,937 $ 1,839 DERMAdoctor 785 1,043 NeutroPhase — 148 Other products 395 237 Total product revenue, net 3,117 3,267 Other revenue, net 7 6 Total sales, net $ 3,124 $ 3,273
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	March 31, December 31, Major distribution partner 2023 2022 Avenova Spray Pharmacy Distributor A 35 % 30 % Major U.S. Retailer A 15 % * % Major U.S. Retailer B 12 % * % Major U.S. Retailer C * % 15 % Avenova Spray Pharmacy Distributor B * % 11 %
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	For the Three Months Ended March 31, 2022 As Previously Reported Selling Commissions Fulfillment Fees As Revised Sales Product revenue, net $ 2,623 $ 298 $ 346 $ 3,267 Product cost of goods sold Product cost of goods sold 1,113 - 346 1,459 Operating expenses Sales and marketing 1,687 298 - 1,985 Net loss (111 ) - - (111 ) Net loss per share attributable to common stockholders (basic and diluted) (0.08 ) - - (0.08 )
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, Numerator 2023 2022 Net loss $ (1,739 ) $ (111 ) Denominator Weighted average shares of common stock outstanding (basic and diluted) 2,035 1,431 Net loss per share attributable to common stockholders (basic and diluted) $ (0.85 ) $ (0.08 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2023 2022 Stock options 121 126 Stock warrants 2,306 1,274 2,427 1,400

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Quoted Prices in Active Significant Markets Other Significant Balance at for Identical Observable Unobservable March 31, Items Inputs Inputs 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 152 152 — — Total assets $ 476 $ 476 $ — $ — Fair Value Measurements Using Quoted Prices in Active Significant Markets Other Significant Balance at for Identical Observable Unobservable December 31, Items Inputs Inputs 2022 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 332 $ 332 $ — $ — Deposit held as a certificate of deposit 152 152 — — Total assets $ 484 $ 484 $ — $ —

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, December 31, 2023 2022 Prepaid inventory $ 122 $ 211 Prepaid insurance 119 146 Prepaid dues and subscriptions 99 43 Prepaid marketing costs 40 24 Prepaid patents 4 12 Tenant allowance — 11 Other 132 113 Total prepaid expenses and other current assets $ 516 $ 560

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, 2023 2022 Raw materials and supplies $ 1,080 $ 1,273 Finished goods 3,205 2,663 Less: Reserve for excess and obsolete inventory (488 ) (499 ) Total inventory, net $ 3,797 $ 3,437

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, 2023 2022 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 425 412 Leasehold improvements 152 152 Total property and equipment, at cost 754 741 Less: accumulated depreciation (635 ) (622 ) Total property and equipment, net $ 119 $ 119

Note 7 - Other Intangible Ass_2

Note 7 - Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Balance at March 31, 2023 Accumulated Gross Amortization Impairment Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (970 ) $ 1,110 Amortizable intangible assets Customer relationships $ 290 $ (51 ) $ (172 ) $ 67 Trade secrets / product formulations 2,890 (410 ) (1,415 ) 1,065 Total other intangible assets $ 5,260 $ (461 ) $ (2,557 ) $ 2,242 Balance at December 31, 2022 Accumulated Gross Amortization Impairment Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (970 ) $ 1,110 Amortizable intangible assets Customer relationships $ 290 $ (48 ) $ (172 ) $ 70 Trade secrets / product formulations 2,890 (375 ) (1,415 ) 1,100 Total other intangible assets $ 5,260 $ (423 ) $ (2,557 ) $ 2,280
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2023 $ 114 2024 153 2025 152 2026 153 Thereafter 560 Total $ 1,132

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2023 2022 Contract liabilities (see Note 14) $ 1,864 $ 1,807 Employee payroll and benefits 402 261 Marketing costs 49 104 Inventory purchases 14 101 Other 480 451 Total accrued liabilities $ 2,809 $ 2,724

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Lease, Cost [Table Text Block]	Lease Costs Three Months Ended March 31, 2023 2022 Operating lease cost $ 130 $ 134 Net lease cost $ 130 $ 134 Other information Operational cash flow used for operating leases $ 106 $ 111 Three Months Ended March 31, 2023 2022 Weighted-average remaining lease term (in years) 4.0 5.0 Weighted-average discount rate 5 % 5 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2023 $ 437 2024 557 2025 439 2026 444 2027 290 Total future minimum lease payments 2,167 Less imputed interest (189 ) Total $ 1,978 Reported as: Operating lease liabilities $ 466 Operating lease liabilities- non-current 1,512 Total $ 1,978

Note 11 - Warrant Liability (Ta

Note 11 - Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	Expected price volatility 79.6 % Expected term (in years) 6.0 Risk-free interest rate 3.43 % Dividend yield 0.0 % Weighted-average fair value of warrants $ 4.55 Expected price volatility 79.5 % Expected term (in years) 5.8 Risk-free interest rate 3.93 % Dividend yield 0.0 % Weighted-average fair value of warrants $ 1.40 Expected price volatility 87 % Expected term (in years) 6.0 Risk-free interest rate 1.31 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 8.75 Expected price volatility 91 % Expected term (in years) 6.0 Risk-free interest rate 1.65 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 7.00 Expected price volatility 79.6 % Expected term (in years) 6.0 Risk-free interest rate 3.43 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 4.55 Expected price volatility 79.5 % Expected term (in years) 5.8 Risk-free interest rate 3.93 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.40 Expected price volatility 79.6 % Expected term (in years) 3.4 Risk-free interest rate 3.58 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 3.50 Expected price volatility 79.5 % Expected term (in years) 3.2 Risk-free interest rate 4.15 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.05

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Fair Value Assumptions of Warrants [Table Text Block]	November 2021 Warrants July 2020 Warrants Expected price volatility 79.6 % 79.6 % Expected term (in years) 5.4 3.4 Risk-free interest rate 3.43 % 3.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.15 $ 0.70 November 2021 Warrants July 2020 Warrants Expected price volatility 79.6 % 79.6 % Expected term (in years) 6.0 3.4 Risk-free interest rate 3.43 % 3.58 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 4.55 $ 3.50
Schedule of Preferred Stock Assumptions [Table Text Block]	Expected price volatility 79.6 % Expected term (in years) 1.3 Risk-free interest rate 3.64 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 8.05 Expected price volatility 79.6 % Expected term (in years) 1.3 Risk-free interest rate 3.64 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 2.10
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2022 2,306 $ 7.70 Warrants granted — $ — Warrants expired — $ — Outstanding at March 31, 2023 2,306 $ 7.70

Note 13 - Equity-based Compen_2

Note 13 - Equity-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Awards Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2022 132 $ 37.99 7.5 $ 69 Options granted 4 $ 1.80 Options forfeited/cancelled (5 ) $ 59.45 Restricted stock units cancelled (7 ) — Outstanding at March 31, 2023 124 $ 38.34 7.3 $ 48 Vested and expected to vest at March 31, 2023 95 $ 49.23 6.9 $ 9 Vested at March 31, 2023 66 $ 65.02 6.1 $ — Exercisable at March 31, 2023 66 $ 65.02 6.1 $ —
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2023 2022 Research and development $ 6 $ 4 Sales and marketing 15 12 General and administrative 54 168 Total stock-based compensation expense $ 75 $ 184
Employees and Directors [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, Assumption 2023 2022 Expected price volatility 154.49 % 160.47 % Expected term (in years) 6.66 6.45 Risk-free interest rate 3.41 % 1.63 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.37 $ 10.21

Note 14 - Distribution Agreem_2

Note 14 - Distribution Agreements (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Product Returns, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2022 $ 1,673 $ 53 $ 81 $ 1,807 Provision related to sales made in current period 254 21 401 676 Payments and customer credits issued (188 ) (8 ) (423 ) (619 ) Balance at March 31, 2023 $ 1,739 $ 66 $ 59 $ 1,864

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Three Months Ended March 31, 2023 2022 Related party revenue: NeutroPhase $ — $ 148 Total related party revenue $ — $ 148 Cost of goods sold: NeutroPhase $ — $ (134 ) Total related party expenses $ — $ (134 )

Note 17 - Segment Reporting (Ta

Note 17 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Three Months Ended Percentage Ended Percentage March 31, of Total Sales, March 31, of Total Sales, 2023 Net 2022 Net Eyecare & Wound Care $ 2,339 75 % $ 2,230 68 % Skincare 785 25 % 1,043 32 % Total sales, net $ 3,124 100 % $ 3,273 100 % Three Months Three Months Ended Percentage Ended Percentage March 31, of Total March 31, of Total 2023 Operating Loss 2022 Operating Loss Eyecare & Wound Care $ (1,335 ) 77 % $ (2,039 ) 86 % Skincare (399 ) 23 % (343 ) 14 % Total operating loss $ (1,734 ) 100 % $ (2,382 ) 100 %

Note 1 - Organization (Details

Note 1 - Organization (Details Textual)		3 Months Ended
	Nov. 15, 2022	Mar. 31, 2023
Number of Reportable Segments		2
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss	$ 3		$ 19
Inventory Valuation Reserves	488	$ 499	499
Goodwill and Intangible Asset Impairment	0	0
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)	970		$ 970
Impairment, Long-Lived Asset, Held-for-Use	$ 0	0
Payment for Product Supply Period (Day)	30 days
Deferred Revenue	$ 307	4
Advertising Expense	326	$ 617
Trade Names [Member]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)	$ 0
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Revenue from Contract with Customer Benchmark [Member] | Distributor Concentration Risk [Member] | Avenova Spray [Member]
Concentration Risk, Percentage	75%	82%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Cash and cash equivalents	$ 3,746	$ 5,362
Restricted cash included in other assets	476	484
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows	$ 4,222	$ 5,846	$ 5,793	$ 7,979

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total sales, net	$ 3,124	$ 3,273
Avenova Spray [Member]
Total sales, net	1,937	1,839
DERMAdoctor [Member]
Total sales, net	785	1,043
NeutroPhase [Member]
Total sales, net	0	148
Other Products [member]
Total sales, net	395	237
Total Product Revenue [Member]
Total sales, net	3,117	3,267
Product and Service, Other [Member]
Total sales, net	$ 7	$ 6

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Distributor A [Member]
Accounts receivable, concentration risk	35%	30%
Major U.S. Retailer A [Member]
Accounts receivable, concentration risk	15%
Major U.S. Retailer C [Member]
Accounts receivable, concentration risk		15%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Revision of Prior Period (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Product revenue, net	$ 3,124	$ 3,273
Product cost of goods sold	1,188	1,459
Sales and marketing	1,653	1,985
Net loss	$ (1,739)	$ (111)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.85)	$ (0.08)
Previously Reported [Member]
Product cost of goods sold		$ 1,113
Sales and marketing		1,687
Net loss		$ (111)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)		$ (0.08)
Revision of Prior Period, Change in Accounting Principle, Adjustment [Member] | Change in Accounting for Selling Commissions [Member]
Product cost of goods sold		$ 0
Sales and marketing		298
Net loss		$ 0
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)		$ 0
Revision of Prior Period, Change in Accounting Principle, Adjustment [Member] | Change in Accounting for Fulfillment Fees [Member]
Product cost of goods sold		$ 346
Sales and marketing		0
Net loss		$ 0
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)		$ 0
Product [Member]
Product revenue, net	$ 3,117	$ 3,267
Product [Member] | Previously Reported [Member]
Product revenue, net		2,623
Product [Member] | Revision of Prior Period, Change in Accounting Principle, Adjustment [Member] | Change in Accounting for Selling Commissions [Member]
Product revenue, net		298
Product [Member] | Revision of Prior Period, Change in Accounting Principle, Adjustment [Member] | Change in Accounting for Fulfillment Fees [Member]
Product revenue, net		$ 346

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net loss	$ (1,739)	$ (111)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares)	2,035	1,431
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.85)	$ (0.08)

Note 2 - Summary of Significa_9

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Anti-dilutive securities (in shares)	2,427	1,400
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	121	126
Warrant [Member]
Anti-dilutive securities (in shares)	2,306	1,274

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Restricted cash held as a certificate of deposit	$ 324	$ 332
Deposit held as a certificate of deposit	152	152
Total assets	476	484
Fair Value, Inputs, Level 1 [Member]
Restricted cash held as a certificate of deposit	324	332
Deposit held as a certificate of deposit	152	152
Total assets	476	$ 484
Fair Value, Inputs, Level 2 [Member]
Restricted cash held as a certificate of deposit	0
Deposit held as a certificate of deposit	0
Total assets	0
Fair Value, Inputs, Level 3 [Member]
Restricted cash held as a certificate of deposit	0
Deposit held as a certificate of deposit	0
Total assets	$ 0

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Prepaid inventory	$ 122	$ 211
Prepaid insurance	119	146
Prepaid dues and subscriptions	99	43
Prepaid marketing costs	40	24
Prepaid patents	4	12
Tenant allowance	0	11
Other	132	113
Total prepaid expenses and other current assets	$ 516	$ 560

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Raw materials and supplies	$ 1,080		$ 1,273
Finished goods	3,205		2,663
Less: Reserve for excess and obsolete inventory	(488)	$ (499)	(499)
Total inventory, net	$ 3,797	$ 3,437	$ 3,437

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Depreciation, Depletion and Amortization	$ 13	$ 30

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property and equipment, at cost	$ 754	$ 741
Less: accumulated depreciation	(635)	(622)
Total property and equipment, net	119	119
Office and Laboratory Equipment [Member]
Property and equipment, at cost	20	20
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	425	412
Leasehold Improvements [Member]
Property and equipment, at cost	$ 152	$ 152

Note 7 - Other Intangible Ass_3

Note 7 - Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 2,557		$ 2,557
Amortization of Intangible Assets	38	$ 91
Other Intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	0	$ 0
DERMAdoctor [Member] | Goodwill and Intangible Asset Impairment [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 2,600

Note 7 - Other Intangible Ass_4

Note 7 - Other Intangible Assets - Schedule of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Trade names, gross	$ 2,080	$ 2,080
Trade names, impairment	(970)	(970)
Trade names, net	1,110	1,110
Amortizable intangible assets, accumulated amortization	(461)	(423)
Amortizable intangible assets, net	1,132
Total other intangible assets	5,260	5,260
Total other intangible assets, impairment	(2,557)	(2,557)
Total other intangible assets, net	2,242	2,280
Customer Relationships [Member]
Amortizable intangible assets, gross	290	290
Amortizable intangible assets, accumulated amortization	(51)	(48)
Amortizable intangible assets, impairment	(172)	(172)
Amortizable intangible assets, net	67	70
Trade Secrets [Member]
Amortizable intangible assets, gross	2,890	2,890
Amortizable intangible assets, accumulated amortization	(410)	(375)
Amortizable intangible assets, impairment	(1,415)	(1,415)
Amortizable intangible assets, net	$ 1,065	$ 1,100

Note 7 - Other Intangible Ass_5

Note 7 - Other Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2023 USD ($)
2023	$ 114
2024	153
2025	152
2026	153
Thereafter	560
Total	$ 1,132

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Contract liabilities (see Note 14)	$ 1,864		$ 1,807
Employee payroll and benefits	402		261
Marketing costs	49		104
Inventory purchases	14		101
Other	480		451
Total accrued liabilities	$ 2,809	$ 2,724	$ 2,724

Note 9 - Line of Credit (Detail

Note 9 - Line of Credit (Details Textual) - Line of Credit [Member] - Bank Midwest [Member] - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Line of Credit Facility, Maximum Borrowing Capacity	$ 500
Long-Term Line of Credit	$ 0	$ 0

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies (Details Textual)	Mar. 31, 2023 ft²
Riverside, Missouri [Member]
Area of Real Estate Property (Square Foot)	19,136

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Operating lease cost	$ 130	$ 134
Net lease cost	130	134
Operational cash flow used for operating leases	$ 106	$ 111
Weighted-average remaining lease term (in years) (Year)	4 years		5 years
Weighted-average discount rate	5%		5%

Note 10 - Commitments and Con_5

Note 10 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
2023	$ 437
2024	557
2025	439
2026	444
2027	290
Total future minimum lease payments	2,167
Less imputed interest	(189)
Total	1,978
Operating lease liabilities	466	$ 453
Operating lease liabilities- non-current	1,512	$ 1,588
Total	$ 1,978

Note 11 - Warrant Liability (De

Note 11 - Warrant Liability (Details Textual) - USD ($)	Mar. 31, 2023	Nov. 10, 2022	Sep. 09, 2022	Jan. 31, 2022	Dec. 31, 2021
September 2022 Warrants [Member]
Warrants and Rights Outstanding		$ 500,000	$ 1,400,000
The November 2021 Warrants [Member]
Warrants and Rights Outstanding		$ 1,300,000		$ 7,500,000	$ 9,600,000
The Amended November 2021 Warrants [Member]
Warrants and Rights Outstanding			$ 3.5
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			803,574
Amended July 2020 Warrants [Member]
Warrants and Rights Outstanding	$ 100,000		$ 300,000
Class of Warrant or Right, Outstanding, Accounting for Subsequent Stock Split (in shares)			77,145

Note 11 - Warrant Liability - T

Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details)	Nov. 10, 2022	Sep. 09, 2022	Sep. 08, 2022	Jan. 31, 2022	Nov. 02, 2021
Measurement Input, Price Volatility [Member] | September 2022 Warrants [Member]
Warrants assumptions	0.795	0.796
Measurement Input, Price Volatility [Member] | The 2021 Warrants [Member]
Warrants assumptions				0.91	0.87
Measurement Input, Price Volatility [Member] | The Amended November 2021 Warrants [Member]
Warrants assumptions		0.796
Measurement Input, Price Volatility [Member] | The November 2021 Warrants [Member]
Warrants assumptions	0.795	0.796	0.796
Measurement Input, Price Volatility [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	0.795	0.796	0.796
Measurement Input, Expected Term [Member] | September 2022 Warrants [Member]
Warrants assumptions	5.8	6
Measurement Input, Expected Term [Member] | The 2021 Warrants [Member]
Warrants assumptions				6	6
Measurement Input, Expected Term [Member] | The Amended November 2021 Warrants [Member]
Warrants assumptions		6
Measurement Input, Expected Term [Member] | The November 2021 Warrants [Member]
Warrants assumptions	5.8	6	5.4
Measurement Input, Expected Term [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	3.2	3.4	3.4
Measurement Input, Risk Free Interest Rate [Member] | September 2022 Warrants [Member]
Warrants assumptions	0.0393	0.0343
Measurement Input, Risk Free Interest Rate [Member] | The 2021 Warrants [Member]
Warrants assumptions				0.0165	0.0131
Measurement Input, Risk Free Interest Rate [Member] | The Amended November 2021 Warrants [Member]
Warrants assumptions		0.0343
Measurement Input, Risk Free Interest Rate [Member] | The November 2021 Warrants [Member]
Warrants assumptions	0.0393	0.0343	0.0343
Measurement Input, Risk Free Interest Rate [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	0.0415	0.0358	0.0358
Measurement Input, Expected Dividend Rate [Member] | September 2022 Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Expected Dividend Rate [Member] | The 2021 Warrants [Member]
Warrants assumptions				0	0
Measurement Input, Expected Dividend Rate [Member] | The Amended November 2021 Warrants [Member]
Warrants assumptions		0
Measurement Input, Expected Dividend Rate [Member] | The November 2021 Warrants [Member]
Warrants assumptions	0	0	0
Measurement Input, Expected Dividend Rate [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	0	0	0
Measurement Input, Share Price [Member] | September 2022 Warrants [Member]
Warrants assumptions	1.40	4.55
Measurement Input, Share Price [Member] | The 2021 Warrants [Member]
Warrants assumptions				7	8.75
Measurement Input, Share Price [Member] | The Amended November 2021 Warrants [Member]
Warrants assumptions		4.55
Measurement Input, Share Price [Member] | The November 2021 Warrants [Member]
Warrants assumptions	1.40	4.55	3.15
Measurement Input, Share Price [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	1.05	3.50	0.70

Note 12 - Stockholders' Equit_2

Note 12 - Stockholders' Equity (Details Textual)				3 Months Ended	12 Months Ended
	Nov. 15, 2022 $ / shares	Sep. 09, 2022 USD ($) $ / shares shares	Oct. 29, 2021 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2019 shares	Apr. 27, 2023 $ / shares	Dec. 31, 2022 $ / shares shares	Nov. 10, 2022 USD ($)	Sep. 08, 2022 USD ($) $ / shares	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 15, 2021 $ / shares shares	Sep. 30, 2020 $ / shares	Jul. 31, 2020 $ / shares
Common Stock, Shares Authorized (in shares)				150,000,000			150,000,000
Preferred Stock, Shares Authorized (in shares)				5,000,000			5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 7.70			$ 7.70
Class of Warrant or Right, Outstanding (in shares)				2,306,000			2,306,000
Class of Warrant or Right, Issued During Period (in shares)				0
The 2022 Private Placement [Member]
Proceeds from Issuance or Sale of Equity, Total | $		$ 3,200,000
The 2022 Private Placement [Member] | Conversion of Series C Preferred Stock to Common Stock [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)		516,750
The 2021 Private Placement Program [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				3,380
The 2021 Private Placement Program [Member] | Conversion of Series B Preferred Stock to Common Stock [Member] | Stock Restatement From Reverse Stock Split [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)			1,071,429
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				2,000			2,000
Series C Preferred Stock [Member] | The 2022 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		3,250
Series B Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 6.30	$ 0.18							$ 0.40
Preferred Stock, Convertible, Conversion Ratio	159
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)		5,556
Preferred Stock, Change in Conversion Price, Income Statement Impact | $		$ 5,700,000
Preferred Stock, Fair Value Disclosure | $		$ 12.5							$ 6,800,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				12,000			12,000
Series B Preferred Stock [Member] | The 2021 Private Placement Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)			15,000
Proceeds from Issuance of Preferred Stock and Preference Stock | $			$ 14,900,000
Preferred Stock, Purchase Price (in dollars per share) | $ / shares			$ 1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 0.40	$ 6.30
Preferred Stock, Convertible, Conversion Ratio			2,500	159
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				11,620
Series B Preferred Stock [Member] | The 2021 Private Placement Program [Member] | Subsequent Event [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares						$ 1.30
Preferred Stock, Convertible, Conversion Ratio						770
The Amended November 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		803,574
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 6.30
Warrants and Rights Outstanding | $		$ 3.5
The Amended July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		77,145
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 6.30
The July 2020 and November 2021 Warrants [Member]
Warrants and Rights Outstanding | $		$ 5,200,000							$ 3,300,000
The 2022 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		327,860
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 6.30
Proceeds from Warrant Exercises | $		$ 2,100,000
Payments of Stock Issuance Costs | $		529,000
Payments of Stock Issuance Costs Allocated to Warrants | $		166,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $		$ 363,000
The 2022 Warrant Reprice Transaction [Member] | Ladenburg Thalmann and Co. Inc. [Member]
Exercise of Warrants, Commission, Percent		8%
The November 2021 Warrants [Member]
Warrants and Rights Outstanding | $								$ 1,300,000		$ 7,500,000	$ 9,600,000
Proceeds from Warrant Exercises | $		$ 700,000
Class of Warrant or Right, Outstanding (in shares)							803,574
The November 2021 Warrants [Member] | Stock Restatement From Reverse Stock Split [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 6.30
Amended July 2020 Warrants [Member]
Warrants and Rights Outstanding | $		$ 300,000		$ 100,000
Proceeds from Warrant Exercises | $		$ 1,400,000
The 2022 Private Placement Short Term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 6.30
The 2022 Private Placement Long Term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 6.30
The 2021 Warrants [Member] | Stock Restatement From Reverse Stock Split [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,071,429
September 2022 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.18
Warrants and Rights Outstanding | $		$ 1,400,000						$ 500,000
The 2019 Ladenburg Warrants [Member] | Stock Restatement From Reverse Stock Split [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 34.65
Class of Warrant or Right, Issued During Period (in shares)					4,799
The July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				59,960
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 57.75
TLF Bio Innovation 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												429
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 23.513
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35

Note 12 - Stockholders' Equit_3

Note 12 - Stockholders' Equity - The Key Assumptions Used to Value the Warrants (Details)	Nov. 10, 2022	Sep. 09, 2022	Sep. 08, 2022
Measurement Input, Price Volatility [Member] | The November 2021 Warrants [Member]
Warrants assumptions	0.795	0.796	0.796
Measurement Input, Price Volatility [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	0.795	0.796	0.796
Measurement Input, Expected Term [Member] | The November 2021 Warrants [Member]
Warrants assumptions	5.8	6	5.4
Measurement Input, Expected Term [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	3.2	3.4	3.4
Measurement Input, Risk Free Interest Rate [Member] | The November 2021 Warrants [Member]
Warrants assumptions	0.0393	0.0343	0.0343
Measurement Input, Risk Free Interest Rate [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	0.0415	0.0358	0.0358
Measurement Input, Expected Dividend Rate [Member] | The November 2021 Warrants [Member]
Warrants assumptions	0	0	0
Measurement Input, Expected Dividend Rate [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	0	0	0
Measurement Input, Share Price [Member] | The November 2021 Warrants [Member]
Warrants assumptions	1.40	4.55	3.15
Measurement Input, Share Price [Member] | Amended July 2020 Warrants [Member]
Warrants assumptions	1.05	3.50	0.70

Note 12 - Stockholders' Equit_4

Note 12 - Stockholders' Equity - Preferred Stock Assumptions (Details) - Series B Preferred Stock [Member]	Sep. 09, 2022	Sep. 08, 2022
Measurement Input, Price Volatility [Member]
Preferred stock assumption	0.796	0.796
Measurement Input, Expected Term [Member]
Preferred stock assumption	1.3	1.3
Measurement Input, Risk Free Interest Rate [Member]
Preferred stock assumption	0.0364	0.0364
Measurement Input, Expected Dividend Rate [Member]
Preferred stock assumption	0	0
Measurement Input, Share Price [Member]
Preferred stock assumption	2.10	8.05

Note 12 - Stockholders' Equit_5

Note 12 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Outstanding warrants (in shares) | shares	2,306
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 7.70
Warrants granted (in shares) | shares	0
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Warrants expired (in shares) | shares	0
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares	$ 0

Note 13 - Equity-based Compen_3

Note 13 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended
	Mar. 31, 2023	Mar. 31, 2017	Oct. 31, 2007	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)					0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 300			$ 300
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 21 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				4,000
Share-Based Payment Arrangement, Expense						$ 184
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				3,650		9,486
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense				$ 75		$ 184
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Payment Arrangement, Expense				$ 0		$ 0
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			10 years
The 2017 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		66,243
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock		4%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	81,417
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	180,143			180,143
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum		10%
The 2017 Omnibus Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		4 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		100%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		110%

Note 13 - Equity-based Compen_4

Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Outstanding awards (in shares)	132
Outstanding, weighted-average exercise price (in dollars per share)	$ 37.99
Outstanding, weighted-average remaining contractual life (Year)	7 years 3 months 18 days	7 years 6 months
Outstanding, aggregate intrinsic value	$ 48		$ 69
Options granted (in shares)	4
Options granted, weighted-average exercise price (in dollars per share)	$ 1.80
Options forfeited/cancelled (in shares)	(5)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)	$ 59.45
Outstanding awards (in shares)	124
Outstanding, weighted-average exercise price (in dollars per share)	$ 38.34
Vested and expected to vest (in shares)	95
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 49.23
Vested and expected to vest, weighted-average remaining contractual life (Year)	6 years 10 months 24 days
Vested and expected to vest, aggregate intrinsic value	$ 9
Vested (in shares)	66
Vested, weighted-average exercise price (in dollars per share)	$ 65.02
Vested, weighted-average remaining contractual life (Year)	6 years 1 month 6 days
Exercisable (in shares)	66
Exercisable, weighted-average exercise price (in dollars per share)	$ 65.02
Exercisable, weighted-average remaining contractual life (Year)	6 years 1 month 6 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units cancelled (in shares)	(7)

Note 13 - Equity-based Compen_5

Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Expected price volatility	154.49%	160.47%
Expected term (Year)	6 years 7 months 28 days	6 years 5 months 12 days
Risk-free interest rate	3.41%	1.63%
Dividend yield	0%	0%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.37	$ 10.21

Note 13 - Equity-based Compen_6

Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation expense		$ 184
General and administrative	$ 75
Research and Development Expense [Member]
Stock-based compensation expense	6	4
Selling and Marketing Expense [Member]
Stock-based compensation expense	15	12
General and Administrative Expense [Member]
Stock-based compensation expense		$ 168
General and administrative	$ 54

Note 14 - Distribution Agreem_3

Note 14 - Distribution Agreements (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue from Contract with Customer, Including Assessed Tax	$ 3,124,000	$ 3,273,000
Avenova Direct [Member]
Revenue from Contract with Customer, Including Assessed Tax	1,600,000	1,800,000
DERMAdoctor [Member]
Contract with Customer, Liability	300,000		$ 200,000
Revenue from Contract with Customer, Including Assessed Tax	785,000	1,043,000
McKesson Corporation [Member] | Avenova Product [Member]
Contract with Customer, Liability, Revenue Recognized	92,000	199,000
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member]
Contract with Customer, Liability	1,500,000		1,600,000
McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member]
Contract with Customer, Rebate Liability, Current	8		$ 0
Costco and Others [Member] | DERMAdoctor [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 100,000	$ 200,000

Note 14 - Distribution Agreem_4

Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Chargebacks, Discounts for Prompt, Payment, and Other [Member]
Balance	$ 1,673
Provision related to sales made in current period	254
Payments and customer credits issued	(188)
Balance	1,739
Other Customer Fees [Member]
Balance	53
Provision related to sales made in current period	21
Payments and customer credits issued	(8)
Balance	66
Rebates [Member]
Balance	81
Provision related to sales made in current period	401
Payments and customer credits issued	(423)
Balance	59
Variable Consideration [Member]
Balance	1,807
Provision related to sales made in current period	676
Payments and customer credits issued	(619)
Balance	$ 1,864

Note 15 - Employee Benefit Pl_2

Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands		3 Months Ended
	Jan. 01, 2022	Mar. 31, 2023	Mar. 31, 2022
The 401K Plan Contribution Level One [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3%
The 401K Plan Contribution Level Two [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2%
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount		$ 32	$ 46

Note 16 - Related Party Trans_3

Note 16 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Related Party [Member]
Accounts Receivable, before Allowance for Credit Loss	$ 0	$ 200

Note 16 - Related Party Trans_4

Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Product cost of goods sold	$ 1,188	$ 1,459
Related Party [Member]
NeutroPhase	0	148
Product cost of goods sold	0	134
NeutroPhase [Member] | Related Party [Member]
NeutroPhase	0	148
Product cost of goods sold	$ 0	$ 134

Note 17 - Segment Reporting (De

Note 17 - Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2023
Number of Reportable Segments	2

Note 17 - Segment Reporting - F

Note 17 - Segment Reporting - Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from Contract with Customer, Including Assessed Tax	$ 3,124	$ 3,273
Operating loss	$ (1,734)	$ (2,382)
Operating loss, percentage	100%	100%
Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 3,117	$ 3,267
Total of Revenue	100%	100%
Optical and Wound Care [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 2,339	$ 2,230
Operating loss	$ (1,335)	$ (2,039)
Operating loss, percentage	77%	86%
Optical and Wound Care [Member] | Product [Member]
Total of Revenue	75%	68%
Skin Care [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 785	$ 1,043
Operating loss	$ (399)	$ (343)
Operating loss, percentage	23%	14%
Skin Care [Member] | Product [Member]
Total of Revenue	25%	32%

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) $ / shares in Units, $ in Thousands	Apr. 27, 2023 USD ($) $ / shares shares	Apr. 26, 2023 $ / shares shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 7.70	$ 7.70
Subsequent Event [Member]
Proceeds from Issuance of Private Placement | $	$ 3,000
Subsequent Event [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 1.30	$ 6.30
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	770	159
Preferred Stock, Convertible, Increase in Shares Issuable (in shares)	7,863,570
Subsequent Event [Member] | Ladenburg Thalmann and Co. Inc. [Member]
Private Placement, Placement Agent Fee, Percentage of Gross Proceeds	8%
Payments of Stock Issuance Costs, Reimbursement of Expenses | $	$ 55
Subsequent Event [Member] | Series B-1 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,538,464
Warrants and Rights Outstanding, Term (Year)	5 years
Subsequent Event [Member] | Series B-2 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,538,464
Warrants and Rights Outstanding, Term (Year)	2 years
Subsequent Event [Member] | Warrant Amendment Agreements [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,724,455
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 1.30	$ 6.30
Subsequent Event [Member] | Series B-1 and B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 1.30
Subsequent Event [Member] | Original Issue Discount Senior Secured Convertible Debentures Due November 1, 2024 [Member]
Debt Instrument, Face Amount | $	$ 3,300
Debt Instrument, Convertible, Number of Equity Instruments	2,538,464
Maximum Percentage of Common Stock Outstanding	19.99%
Debt Instrument, Convertible, Maximum Issuable Shares Per Holder (in shares)	438,669
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 1.30
Debt Instrument, Monthly Redemption, Aggregate Principal Amount	0.556
Debt Instrument, Monthly Redemption, Multiplier in Cash	1.10
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90%
Debt Instrument, Convertible, Threshold Trading Days	10
Debt Instrument, Default, Interest Rate	18%